Acquired erythropoietic protoporphyria: A systematic review of the literature

Photodermatol Photoimmunol Photomed. 2020 Jan;36(1):29-33. doi: 10.1111/phpp.12501. Epub 2019 Aug 21.

Abstract

Background: Erythropoietic protoporphyria (EPP) is a semi-dominantly inherited porphyria presenting with photosensitivity during early childhood. Acquired EPP has been reported; however, data regarding this rare disorder are scarce.

Purpose: To evaluate the characteristics of acquired EPP.

Methods: A comprehensive search of PubMed, Google Scholar, ScienceDirect, and clinicaltrials.gov databases was performed by three reviewers. Studies describing patients with acquired EPP were included. Additionally, we present an index case of a 26-year-old patient who acquired clinically and biochemically typical EPP in association with myelodysplastic syndrome (MDS).

Results: We included 20 case reports describing 20 patients. Most (80%) patients were male of mean age 58 ± 13 years. In all patients, acquired EPP was associated with hematological disease, most commonly MDS (85%) followed by myeloproliferative disease (10%). In 86% of cases, hematological disease led to abnormality or somatic mutation in chromosome 18q (the locus of the ferrochelatase gene). The mean erythrocyte protoporphyrin IX concentration was very high (4286 μg/dL). Most (90%) patients presented with photosensitivity, 20% experienced blistering, and 25% presented with hepatic insufficiency, both uncommon in EPP. In 55% of patients, hematological disease was diagnosed after occurrence of cutaneous symptoms. Beta-carotene led to partial control of symptoms in 5 patients and resolution in another patient. Azacitidine treatment of MDS led to resolution of cutaneous symptoms in three patients.

Conclusion: We present the distinct features of acquired EPP and highlight that any patient presenting with new-onset photosensitivity, irrespective of age should be evaluated for porphyria.

Keywords: acquired; erythropoietic protoporphyria; inherited.

Publication types

  • Case Reports
  • Systematic Review

MeSH terms

  • Adult
  • Aged
  • Azacitidine / therapeutic use*
  • Chromosomes, Human, Pair 18 / genetics
  • Chromosomes, Human, Pair 18 / metabolism
  • Erythrocytes / metabolism
  • Female
  • Ferrochelatase / genetics
  • Ferrochelatase / metabolism
  • Genetic Loci
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / metabolism
  • Photosensitivity Disorders* / chemically induced
  • Photosensitivity Disorders* / drug therapy
  • Photosensitivity Disorders* / genetics
  • Photosensitivity Disorders* / metabolism
  • Protoporphyria, Erythropoietic* / chemically induced
  • Protoporphyria, Erythropoietic* / drug therapy
  • Protoporphyria, Erythropoietic* / genetics
  • Protoporphyria, Erythropoietic* / metabolism
  • Protoporphyrins / genetics
  • Protoporphyrins / metabolism
  • beta Carotene / therapeutic use*

Substances

  • Protoporphyrins
  • beta Carotene
  • protoporphyrin IX
  • Ferrochelatase
  • Azacitidine